Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Eisai Settles Lenvima Patent Suit with Sun Pharma
March 26, 2024
- EMA Panel Gives Go-Ahead for Xtandi Use in Earlier Setting: Astellas
March 26, 2024
- Boehringer’s Brigimadlin Earns Sakigake Designation
March 26, 2024
- Daiichi Sankyo Files MMR Vaccine in Japan
March 26, 2024
- Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
- Lilly, Nippon Shinyaku Pair Up on Blood Cancer Med in Japan
March 26, 2024
- Daiichi Sankyo Eyes 7 Additional Indications for Enhertu by 2026
March 25, 2024
- Ono Hooks Up with Oxford on Drug Discovery Research
March 25, 2024
- EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
- Iclusig Gets Additional FDA Nod for Iclusig in Ph+ ALL: Takeda
March 25, 2024
- Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk
March 25, 2024
- Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
- Japan, US CROs to Collaborate to Address Drug Lags/Losses
March 22, 2024
- Astellas Gives 1.5% Pay Raise to Acquire Best Talents
March 22, 2024
- FDA Clears Orchard’s Lenmeldy Gene Therapy for MLD
March 22, 2024
- Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
March 21, 2024
- Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
- Arexvy Already January GP Rep Promotion Champion, Tarlige Tops HP Ranking
March 21, 2024
- SanBio Chief Baffled by Planned Advisory Session over Lead Cell Therapy
March 21, 2024
- JCR Hits 1st Milestone in Alexion Collab for Neurodegenerative Disease
March 21, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…